Research on ASPS presented at the conference of the “American College of Medical Genetics”
Dr. Shamini Selvarajah presented a summary of her studies on Alveolar Soft Part Sarcoma at the 2011 ACMG Annual Clinical Genetics Meeting that took place at the Vancouver Convention Center, Vancouver, BC, Canada. Dr. Selvarajah is one of the dedicated scientists from the Dana Farber Cancer Institute in Boston. They study ASPS relentlessly, aiming to […]
Register Now to Join Team ASPS in the 2011 PMC Bike Ride
Since its inception, the iCureASPS organization has transferred more than a quarter million dollars to keep up research, and clinical trials that aim to find a cure for ASPS. I would like to thank the ASPS community, friends, and family who are supporting us in our goal of finding a cure for ASPS. Please make […]
Tumor Expression Profile of Alveolar Soft Part Sarcoma May Pave the Way for New Treatments at The Dana Farber Cancer Institute
Scientists from the group of Dr. Massimo Loda reported the results of an extensive study that aims to identify potential therapeutic targets for ASPS last Friday. The research team, comprised of Shamini Selvarajah (PhD), Eleanor Chen (MD, PhD), and Saumyadipta Pyne (PhD), used cDNA microarray technology (gene expression array) to examine the expression of 18,401 […]
PMC 2010 Fund Raiser
Dear ASPS Community! This coming weekend in August 2010, Team ASPS will ride in the Pan-Massachusetts Challenge (PMC) for the 7th time! The PMC is a bike-a-thon that crosses Massachusetts to raise money for cancer research and clinical trials at the Dana-Farber Cancer Institute in Boston. I am asking you to sponsor our team bike […]
Event Summary: The second Annual Knockin’ Down ASPS Event in the memory of Anthony Salisbury (AJ)
The second Annual Knockin’ Down ASPS Event in the memory of Anthony Salisbury (AJ) took place on April 10th, 2010. Over $16,000 were raised this year, which were donated directly to the laboratory of Dr. Glenn Dranoff at the Dana Farber Cancer Institute in Boston in favor of his efforts of finding a cure for […]
Minimally Invasive Procedures for Tumor Ablation
For Alveolar Soft Part Sarcoms patients the use of aggressive surgery, appropriate diagnostic imaging, and long-term surveillance for metastases are critical to achieve long-term survival (Kayton et al 2006). When surgery is not possible, then local treatment like tumor ablation may be considered. In the past we discussed the benefits of Stereotactic Radiosurgery (SRS). There are different […]
Second Fundraiser in the Memory of Anthony Salisbury (AJ)
On January 26 2009, we lost Anthony Salisbury (AJ) to ASPS. AJ’s fiancée, family and friends remain committed to finding a cure for ASPS. In February 2009, they organized “Knockin’ Down ASPSâ€, the first fundraiser in AJ’s memory. This year, on Saturday, April 10, the second AJ memorial fundraiser, “Knockin’ Down ASPS” will take place. […]
Potential Therapeutic Targets in Alveolar Soft Part Sarcoma – by Dr. Dina Lev
Dr. Dina Lev, from the Cancer Biology and the Sarcoma Research Center at the University of Texas M. D. Anderson has published a new study on Alveolar Soft Part Sarcoma. Her study appeared in the Journal of Histopathology. The aim of this study was to evaluate the expression of potential gene therapeutic targets in a cohort of […]
Team ASPS Races in PMC 2009 to Raise Funds for a Cure
During the first weekend of August, Team ASPS participated in their sixth Pan-Massachusetts Challenge (PMC) bike ride. This bike-a-thon crosses Massachusetts to raise money for cancer research and clinical trials at the Dana-Farber Cancer Institute in Boston. Donations raised by Team ASPS are restricted for research and clinical trials that aim to find a cure […]
Cediranib (AZD2171): Phase II Study in Patients With Alveolar Soft Part Sarcoma
Cediranib (Recentin, AZD2171) is an inhibitor of VEGF (Vascular Endothelial Growth Factor) receptors. Therefore, the drug inhibits angiogenesis: the formation of new blood vessels. Angiogenesis, in the context of cancer, enables blood supply to tumors, resulting in tumor growth and spread. Cediranib is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral […]